Diagnostic utility of C-reactive protein to albumin ratio as an early warning sign in hospitalized severe COVID-19 patients.


Journal

International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259

Informations de publication

Date de publication:
Feb 2021
Historique:
received: 23 10 2020
revised: 24 11 2020
accepted: 06 12 2020
pubmed: 22 12 2020
medline: 3 2 2021
entrez: 21 12 2020
Statut: ppublish

Résumé

C-reactive protein-to-albumin ratio (CAR) has been used as an indicator of prognosis in various diseases. Here, we intended to assess the CAR's diagnostic power in early differentiation of hospitalized severe COVID-19 cases. In this retrospectively designed study, we evaluated 197 patients in total. They were divided into two groups based on their severity of COVID-19 as non-severe (n = 113) and severe (n = 84). The comparison of groups' demographic data, comorbidities, clinical symptoms, and laboratory test results were done. Laboratory data of the patients within the first 24 h after admission to the hospital were evaluated. The calculation of receiver operating characteristic (ROC) curve was used to determine the diagnostic power of CAR in differentiating severity of COVID-19. Independent risk factors predictive of COVID-19 severity were determined by using logistic regression analysis. Although lymphocyte count levels were lower, severe COVID-19 patients had higher mean age, higher levels of neutrophil count, CRP, aspartate aminotransferase (AST), ferritin, and prothrombin time (P < 0.05). Compared with non-severe patients (median, 0.23 [IQR = 0.07-1.56]), patients with severe COVID-19 had higher CAR levels (median, 1.66 [IQR = 0.50-3.35]; P < 0.001). Age (OR = 1.046, P = 0.003), CAR (OR = 1.264, P = 0.037), and AST (OR = 1.029, P = 0.037) were independent risk factors for severe COVID-19 based on the multivariate logistic regression analysis. ROC curve analysis assigned 0.9 as the cut-off value for CAR for differentiation of severe COVID-19 (area under the curve = 0.718, 69.1% sensitivity, 70.8% specificity, P < 0.001). CAR is a useful marker in early differentiation of severity in patients hospitalized due to COVID-19 that have longer hospital stay and higher mortality.

Identifiants

pubmed: 33348293
pii: S1567-5769(20)33752-8
doi: 10.1016/j.intimp.2020.107285
pmc: PMC7833970
pii:
doi:

Substances chimiques

Albumins 0
Biomarkers 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

107285

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Références

PLoS One. 2018 Jan 3;13(1):e0190410
pubmed: 29298330
Inflamm Res. 2006 May;55(5):216-20
pubmed: 16830109
J Surg Oncol. 2016 Dec;114(7):895-899
pubmed: 27696432
J Med Virol. 2020 Oct;92(10):2152-2158
pubmed: 32406952
J Clin Invest. 2003 Jun;111(12):1805-12
pubmed: 12813013
Sci China Life Sci. 2020 Nov;63(11):1678-1687
pubmed: 32567003
J Med Invest. 2014;61(3-4):361-8
pubmed: 25264055
Front Oncol. 2019 Feb 21;9:89
pubmed: 30847301
Onco Targets Ther. 2017 Nov 02;10:5255-5261
pubmed: 29138578
Clin Med (Lond). 2020 Sep;20(5):463-467
pubmed: 32934038
Int J Colorectal Dis. 2011 Apr;26(4):473-81
pubmed: 21190025
Front Med (Lausanne). 2020 Nov 03;7:566591
pubmed: 33224959
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Clin Med (Lond). 2009 Feb;9(1):30-3
pubmed: 19271597
Am J Med. 2017 Dec;130(12):1465.e11-1465.e19
pubmed: 28803138
J Med Virol. 2020 Jul;92(7):856-862
pubmed: 32281668
J Clin Virol. 2020 Jun;127:104364
pubmed: 32311650
Mol Psychiatry. 2020 Jun;25(6):1301-1311
pubmed: 29895893
Ann Surg Oncol. 2015 Mar;22(3):803-10
pubmed: 25190127
J Clin Virol. 2020 Jun;127:104370
pubmed: 32344321
Int J Infect Dis. 2020 May;94:128-132
pubmed: 32251805
Front Immunol. 2018 Apr 13;9:754
pubmed: 29706967
JAMA Neurol. 2017 Jun 1;74(6):660-667
pubmed: 28384752
Med Mal Infect. 2020 Jun;50(4):332-334
pubmed: 32243911
PLoS One. 2013;8(3):e59321
pubmed: 23555017

Auteurs

Inanc Karakoyun (I)

University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Biochemistry, Izmir, Turkey. Electronic address: inanckara70@gmail.com.

Ayfer Colak (A)

University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Biochemistry, Izmir, Turkey.

Melda Turken (M)

University of Health Sciences, Tepecik Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Izmir, Turkey.

Zeynep Altin (Z)

University of Health Sciences, Tepecik Training and Research Hospital, Department of Internal Medicine, Izmir, Turkey.

Fatma Demet Arslan (FD)

University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Biochemistry, Izmir, Turkey.

Veli Iyilikci (V)

University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Biochemistry, Izmir, Turkey.

Nisel Yilmaz (N)

University of Health Sciences, Tepecik Training and Research Hospital, Department of Medical Microbiology, Izmir, Turkey.

Sukran Kose (S)

University of Health Sciences, Tepecik Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Izmir, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH